Research programme: epoxyeicosanoids analogues - OMEICOS Therapeutics

Drug Profile

Research programme: epoxyeicosanoids analogues - OMEICOS Therapeutics

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Delbruck Center for Molecular Medicine; University of Texas Southwestern Medical Center
  • Developer OMEICOS Therapeutics
  • Class Cardiovascular therapies; Epoxy compounds; Eye disorder therapies; Small molecules; Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atrial fibrillation; Eye disorders; Myocardial infarction; Ventricular arrhythmias
  • Research Acute kidney injury

Most Recent Events

  • 10 Oct 2017 Early research in Acute kidney injury in Germany (PO) (Omeicos Therapeutics pipeline, October 2017)
  • 10 Oct 2017 Preclinical trials in Myocardial infarction in Germany (PO) (Omeicos Therapeutics pipeline, October 2017)
  • 10 Oct 2017 Preclinical trials in Ventricular arrhythmias in Germany (PO) (Omeicos Therapeutics pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top